Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Operating Margin (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Operating Margin data on record, last reported at 5.26% in Q4 2025.

  • For Q4 2025, Operating Margin rose 3152.0% year-over-year to 5.26%; the TTM value through Dec 2025 reached 15.72%, up 5018.0%, while the annual FY2025 figure was 15.72%, 5018.0% up from the prior year.
  • Operating Margin reached 5.26% in Q4 2025 per TARS's latest filing, up from 12.24% in the prior quarter.
  • Across five years, Operating Margin topped out at 33.07% in Q2 2021 and bottomed at 4274.56% in Q4 2021.
  • Average Operating Margin over 5 years is 732.67%, with a median of 66.94% recorded in 2024.
  • The widest YoY moves for Operating Margin: up 412395bps in 2022, down -365375bps in 2022.
  • A 5-year view of Operating Margin shows it stood at 4274.56% in 2021, then skyrocketed by 96bps to 150.61% in 2022, then tumbled by -126bps to 339.94% in 2023, then surged by 89bps to 36.77% in 2024, then skyrocketed by 86bps to 5.26% in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Margin were 5.26% in Q4 2025, 12.24% in Q3 2025, and 21.61% in Q2 2025.